Amgen 10-Qquarter ended 2026-03-31

Executive Summary

Amgen’s Q1 2026 revenue grew 6% as higher product volume and newer medicines outweighed falling prices and erosion in established products. Operating income more than doubled, but a prior-year impairment and lower acquisition-related amortization explain much of that improvement; net income rose only 5% as equity-investment gains reversed. The company is investing more in its pipeline and manufacturing while carrying substantial debt. For investors, the opportunity is a broader set of growth products; the principal tests are whether they can replace biosimilar-exposed sales and withstand pricing, regulatory and tax pressures.

Key Financial Highlights

• Revenue drivers: Product volume rose 9%, partly offset by 2% lower net selling prices and a 2% inventory headwind. Other revenue increased from $276M, reflecting higher partner revenue and royalties.
• Earnings quality: The “Other” operating expense line swung from an $830M expense to a $113M benefit, including the effect of an $800M Otezla impairment in Q1 2025. Equity securities produced a $143M loss vs a $1.30B gain a year earlier; these swings make the operating-income increase a poor measure of underlying growth.
• Investment and cash conversion: R&D rose 16% to $1.72B, including later-stage programs. Operating cash flow rose from $1.39B, while capital expenditures increased from $411M, mainly for manufacturing expansion; free cash flow rose from $980M.
• Financing and capital return: Amgen issued $4.0B of debt and paid $1.36B in dividends. It repurchased no shares; common shares outstanding rose from 538.8M to 539.7M. The $6.8B remaining repurchase authorization did not reduce the share count this quarter.

Business Developments

Amgen’s growth mix is shifting toward cardiovascular, rare-disease and oncology products. Repatha rose 34% to $876M; UPLIZNA reached $262M vs $91M; and IMDELLTRA/IMDYLLTRA reached $258M vs $81M. These gains offset pressure on Prolia, down 34% to $727M, XGEVA, down 27% to $411M, and ENBREL, down 37% to $320M. Management expects faster Prolia and XGEVA erosion following biosimilar launches.

Management is increasing later-stage pipeline spending, including on MariTide, and estimates ≈$2.6B of capital-project investment in 2026. An April Phase 3 study of subcutaneous TEPEZZA delivered by on-body injector met its primary endpoint, offering a potential alternative to intravenous administration. These investments could diversify future growth, but they raise current spending before commercial returns are established.

Risk Assessment

• Pricing and competitive erosion: Biosimilars are cutting Prolia and XGEVA sales, while Medicare’s lower set price for ENBREL took effect on 1/1/2026 and Otezla faces one from 2027; wider discounts and access restrictions could further compress profitability.
• TAVNEOS regulation: The Food and Drug Administration proposed withdrawing approval over serious, including fatal, liver injury and concerns about effectiveness evidence; the product remains marketed, but restrictions or withdrawal could also put its $2.4B developed-technology carrying value at risk.
• Tax litigation: Disputed federal assessments total $3.6B for 2010–2012 and $5.1B for 2013–2015, plus interest and an asserted $2.0B of penalties; potential payments could substantially exceed accruals, although repatriation-tax offsets may apply.
• Debt and refinancing: Debt at carrying value of $57.3B and Q1 net interest expense of $657M make cash generation important to funding investment, dividends and maturities.
• Investment valuation: Amgen’s ≈17% BeOne Medicines stake was valued at $5.6B at quarter-end; its mark-to-market movements can materially distort reported earnings without reflecting medicine sales.
• Operational resilience: Dependence on third-party technology, suppliers and three primary U.S. wholesalers creates exposure to cyber incidents or outages that could interrupt patient access and sales.

Strategic Outlook and Investor Actionables

Amgen is using cash flow and new borrowing to fund pipeline development and manufacturing capacity as older products lose pricing power. The investment case depends on growth products scaling faster than established-product erosion, without a material TAVNEOS setback or adverse tax outcome. Monitor next quarter:

• Product replacement: Repatha, UPLIZNA and IMDELLTRA/IMDYLLTRA sales growth vs Prolia, XGEVA and ENBREL declines; narrowing net product-sales growth would weaken the thesis.
• Investment returns: R&D and capital expenditures vs operating cash flow and free cash flow; sustained cash conversion would support the spending program and dividend.
• Binary developments: TAVNEOS withdrawal proceedings and the tax case, whose decision is not expected before H2 2026; either adverse outcome could outweigh incremental commercial progress.